```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 9027 Introduced in House (IH)]

<DOC>

116th CONGRESS
  2d Session
                                H. R. 9027

 To authorize the Patient-Centered Outcomes Research Institute to fund 
     research of the symptoms of COVID-19, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           December 18, 2020

  Mr. Beyer introduced the following bill; which was referred to the 
 Committee on Energy and Commerce, and in addition to the Committee on 
   Ways and Means, for a period to be subsequently determined by the 
  Speaker, in each case for consideration of such provisions as fall 
           within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL

 
 To authorize the Patient-Centered Outcomes Research Institute to fund 
     research of the symptoms of COVID-19, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``COVID-19 Long Haulers Act''.

SEC. 2. AUTHORIZATION TO FUND RESEARCH OF THE LONG-TERM SYMPTOMS OF 
              COVID-19 BY THE PATIENT-CENTERED OUTCOMES RESEARCH 
              INSTITUTE.

    (a) In General.--The Patient-Centered Outcomes Research Institute 
under section 1181(b) of the Social Security Act (42 U.S.C. 1320e(b)) 
shall fund research described in subsection (b).
    (b) Research Described.--For purposes of subsection (a), research 
described in this subsection shall include--
            (1) prior to creating a patient registry described in 
        paragraph (2), survey existing patient registries that include 
        individuals experiencing post-acute sequelae of COVID-19;
            (2) creating a patient registry for those with COVID-19 
        with information that--
                    (A) contains the--
                            (i) symptoms that arise while an individual 
                        is actively infected with COVID-19 and that 
                        resolve while such individual is actively 
                        infected;
                            (ii) symptoms that arise while an 
                        individual is actively infected with COVID-19 
                        and that extend after the infection has 
                        resolved;
                            (iii) symptoms that arise after an 
                        individual is actively infected with COVID-19 
                        and that endure and that the clinician of such 
                        individual has reason to suspect were related 
                        to the COVID-19 diagnosis;
                            (iv) symptoms that arise in an individual 
                        that may be related to COVID-19 but a diagnosis 
                        of COVID-19 was not obtained and cannot be 
                        identified due to a lack of antibodies;
                            (v) treatments of individuals after primary 
                        diagnosis to COVID-19 and the effectiveness of 
                        such treatments disaggregated by age, gender, 
                        and race or ethnicity; and
                            (vi) any other relevant questions or issues 
                        related to individuals who experience a 
                        diagnosis of, treatment for, and management of 
                        care with COVID-19;
                    (B) synthesizes information relating to individuals 
                experiencing post-acute sequelae of COVID-19 identified 
                from the survey described in paragraph (1) and 
                information under the patient registry described in 
                paragraph (2); and
            (3) outreach and inclusion (as appropriate) individuals 
        from communities with traditional health disparities and 
        inequities.
    (c) Report.--Not later than 1 year after the establishment of the 
synthesized patient registry described in subsection (a)(2), and 
annually thereafter, the Patient-Centered Outcomes Research Institute 
shall submit data, findings, and information with respect to the status 
of the patient registry (including progress, barriers, and issues) to 
Congress and the President.
    (d) Authorization of Appropriations.--There is hereby authorized 
$30,000,000 for fiscal year 2021 to carry out this section, which shall 
remain available until expended.

SEC. 3. AUTHORIZATION OF APPROPRIATIONS FOR RESEARCH WITH RESPECT TO 
              INDIVIDUALS EXPERIENCING POST-ACUTE SEQUELAE OF COVID-19 
              BY THE NIH.

    (a) In General.--The Director of the National Institutes of Health 
conduct research with respect to individuals experiencing post-acute 
sequelae of COVID-19.
    (b) Authorization of Appropriations.--There is hereby authorized 
$100,000,000 for fiscal year 2021 to carry out this section, which 
shall remain available until expended.
                                 <all>
```